Abstract
Radioiodine ((131)I) therapy is used in patients with papillary and follicular thyroid carcinoma for ablation of thyroid remnants and for treatment of persistent or recurrent disease. It should be used selectively, i.e. only in those patients for whom a clinical benefit may be expected.
MeSH terms
-
Adenocarcinoma, Follicular / pathology
-
Adenocarcinoma, Follicular / radiotherapy*
-
Adenocarcinoma, Follicular / surgery
-
Adult
-
Carcinoma, Papillary / pathology
-
Carcinoma, Papillary / radiotherapy*
-
Carcinoma, Papillary / surgery
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Contraindications
-
Female
-
Follow-Up Studies
-
Humans
-
Infertility / etiology
-
Iodine / metabolism
-
Iodine Radioisotopes / adverse effects
-
Iodine Radioisotopes / pharmacokinetics
-
Iodine Radioisotopes / therapeutic use*
-
Lactation
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm, Residual
-
Neoplasms, Radiation-Induced / etiology
-
Pregnancy
-
Pregnancy Complications, Neoplastic / therapy
-
Prognosis
-
Radiopharmaceuticals / adverse effects
-
Radiopharmaceuticals / pharmacokinetics
-
Radiopharmaceuticals / therapeutic use*
-
Radiotherapy Dosage
-
Radiotherapy, Adjuvant
-
Survival Analysis
-
Thyroid Neoplasms / pathology
-
Thyroid Neoplasms / radiotherapy*
-
Thyroid Neoplasms / surgery
-
Thyroidectomy
Substances
-
Iodine Radioisotopes
-
Radiopharmaceuticals
-
Iodine